Form 4: Precision BioSciences Executive J. Jefferson Smith Reports Stock Transactions

J. Jefferson Smith, Chief Research Officer at Precision BioSciences, reports the vesting of restricted stock units and a sale of shares to cover tax obligations.

Summary

• J. Jefferson Smith, Chief Research Officer of Precision BioSciences, filed a Form 4 detailing changes in beneficial ownership.
• On June 7, 2024, Smith vested 163 Restricted Stock Units (RSUs), each representing one share of Precision BioSciences common stock.
• On June 10, 2024, Smith sold 50 shares of common stock at an average price of $11.79 to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Smith directly owns 68,559 shares of Precision BioSciences common stock and indirectly owns 7,931 shares through a Charitable Remainder Unitrust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine executive compensation activity (vesting of RSUs and sale of shares for tax purposes). There's no indication of significant positive or negative developments.

Positives

• The vesting of RSUs indicates that Smith has met the service requirements associated with the grant, suggesting continued involvement with the company.

Negatives

• The sale of shares, even if for tax purposes, could be perceived negatively by some investors, although the document clarifies it was solely to cover tax obligations.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term price volatility.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. The sale of shares to cover taxes is a common practice.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates